Research deal delivers RNAi drugs
Philips and RXi Pharmaceuticals are to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference (RNAi).

According to Philips, compounds based on RNAi represent a promising new class of drugs for the targeted treatment of a number of diseases, including cancer and cardiovascular disease.
Currently, however, one of the greatest challenges in developing RNAi-based therapeutics is finding ways to deliver them to their target while keeping them fully active.
The joint research programme between Philips and US-based RXi will address this challenge by exploring, in preclinical studies, the possibility of using RXi’s sd-rxRNA (self-delivering rxRNA) in conjunction with Philips’ ultrasound technology to achieve the targeted delivery and monitoring of RNAi-based compounds in cells.
‘The development of ultrasound techniques that could non-invasively trigger the delivery of new drug formats such as RNAi therapeutics at a targeted location opens up exciting possibilities for advancing personalised medicine,’ said Henk van Houten, senior vice president of Philips Research and head of the healthcare research programme.
‘The most important technological challenges that need to be addressed in order to realise the promise of RNAi-based approaches to treating various human disorders are efficient and safe delivery of the RNAi compounds to the targeted organs, and uptake of these compounds by relevant cells,’ said Noah D Beerman, president and chief executive officer at RXi.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Fusion inches closer as ITER completes magnet system
The problem with a Tokamak shape for the fusion plasma, is that the magnetic field from the central solenoid reduces from the centre outwards, leading...